Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

France's Sanofi-Aventis Launches Research Outpost, Clinical Trial Workshops In Western China Region Torn By 2008 Earthquake

This article was originally published in PharmAsia News

Executive Summary

BEIJING - The Paris-headquartered Sanofi-Aventis is creating a small research base in the western Chinese province of Sichuan, the region that is still recovering after being hit by a magnitude 7.9 earthquake in mid-2008

You may also be interested in...



France’s Sanofi-Aventis Creating Joint Lab On Regenerative Medicine & Stem Cell Research With Beijing Hospital

BEIJING - To expand a matrix of partnerships with Chinese academic centers, the Paris-headquartered Sanofi-Aventis is launching a joint laboratory on regenerative medicine with the Xuanwu Hospital in the Chinese capital, according to Marc Cluzel, Sanofi's senior vice president for research and development

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070152

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel